Portola Pharmaceuticals INC (PTLA) Shareholder Cormorant Asset Management LLC Cut Stake

March 14, 2018 - By Vivian Park

Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It is positive, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Jacobs Levy Equity Management Inc invested in 6,950 shares. Pnc Fincl Grp Inc holds 507 shares. Hall Laurie J Trustee has 190 shares for 0.01% of their portfolio. Loring Wolcott Coolidge Fiduciary Ltd Liability Partnership Ma reported 10 shares stake. 38,664 were accumulated by Parametric Portfolio Ltd Liability Company. Emerald Mutual Fund Advisers Trust holds 0.84% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 374,908 shares. Stifel Fincl Corporation invested 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Balyasny Asset Llc, a Illinois-based fund reported 5,300 shares. The Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Cormorant Asset Management Ltd Limited Liability Company, a Massachusetts-based fund reported 500,000 shares. Northern Trust holds 0.01% or 687,985 shares in its portfolio. Sectoral Asset Mngmt stated it has 506,414 shares. Hbk LP invested in 117,680 shares or 0.05% of the stock. Century Companies reported 51,373 shares or 0% of all its holdings. 28,614 were accumulated by Teachers Retirement Systems Of The State Of Kentucky.

Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $563,950 activity.

Cormorant Asset Management Llc decreased its stake in Portola Pharmaceuticals Inc (PTLA) by 44.44% based on its latest 2017Q3 regulatory filing with the SEC. Cormorant Asset Management Llc sold 400,000 shares as the company’s stock rose 22.73% with the market. The hedge fund held 500,000 shares of the health care company at the end of 2017Q3, valued at $27.02M, down from 900,000 at the end of the previous reported quarter. Cormorant Asset Management Llc who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.40B market cap company. The stock increased 0.69% or $0.25 during the last trading session, reaching $36.7. About 629,758 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since March 14, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Cormorant Asset Management Llc, which manages about $841.40 million and $566.36M US Long portfolio, upped its stake in Omeros Corp (NASDAQ:OMER) by 400,000 shares to 1.70M shares, valued at $36.75 million in 2017Q3, according to the filing. It also increased its holding in Mersana Therapeutics by 215,751 shares in the quarter, for a total of 295,549 shares, and has risen its stake in Anaptysbio Inc.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on May, 14. They expect $-1.54 EPS, down 108.11 % or $0.80 from last year’s $-0.74 per share. After $-1.41 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 9.22 % negative EPS growth.

More recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Globenewswire.com which released: “Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for …” on February 20, 2018. Also Zacks.com published the news titled: “Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump March 12, 2018” on March 12, 2018. Streetinsider.com‘s news article titled: “Portola Pharma (PTLA) Announces New Interim Results from Ongoing ANNEXA-4 …” with publication date: March 12, 2018 was also an interesting one.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $69.50’s average target is 89.37% above currents $36.7 stock price. Portola Pharmaceuticals had 38 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Wednesday, December 13. Oppenheimer has “Buy” rating and $80.0 target. The rating was maintained by Credit Suisse on Tuesday, March 13 with “Outperform”. Credit Suisse maintained it with “Neutral” rating and $25 target in Friday, August 19 report. Cowen & Co maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Monday, June 26. Cowen & Co has “Buy” rating and $7000 target. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Tuesday, December 27. Credit Suisse has “Outperform” rating and $29 target. Credit Suisse upgraded the stock to “Outperform” rating in Thursday, August 24 report. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Neutral” rating by Citigroup on Friday, August 19. The company was maintained on Thursday, February 22 by Morgan Stanley. The stock has “Outperform” rating by Oppenheimer on Friday, February 24. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Friday, December 1 by Goldman Sachs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.